You are here

Hoth Therapeutics, Inc. Announces the Addition of Dr. Stefanie Johns, Ph.D. to the Company's Scientific Advisory Board

NEW YORK, March 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH),  a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Stefanie Johns  to the Company's Scientific Advisory Board.  The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform and other therapeutics.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

Dr. Stefanie Johns, Ph.D. is the Associate Director, Regulatory Affairs at Enable Injections, LLC, a company specializing in the development and manufacture of advanced wearable infusion devices for use in combination products.  Dr. Johns completed her graduate work in protein biochemistry at the University of Cincinnati College of Medicine under the direction of Dr. Andrew Herr, Ph.D., whom also contributed to the development of the BioLexa Platform technology.  After graduate school, Dr. Johns joined Xavier Health Initiatives as the Program Manager where she assisted with collaborative initiatives with both pharmaceutical and medical device industry leaders, division leaders from the United States Food and Drug Administration, and members of the Senate Health, Education Labor & Pensions committee. She continued her career in regulatory affairs providing strategic regulatory guidance for medical device, drug, and drug-device combination product development programs at Meridian Bioscience and Camargo Pharmaceutical Services. While at Camargo, Dr. Johns led the planning and implementation of the early regulatory strategy for the BioLexa program. 

Dr. Johns commented, "I am excited to continue working with Hoth Therapeutics on the development of the BioLexa Platform as a novel therapeutic for treatment of dermatological and chronic wound disorders. Chronic dermatological diseases, including atopic dermatitis, cause significant burden on patients and their families and it is important to have novel treatment options available, particularly for patients whose disease is not currently controlled by existing therapies."

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.

Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Prospectus, dated February 14, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-the-addition-of-dr-stefanie-johns-phd-to-the-companys-scientific-advisory-board-300814376.html

SOURCE Hoth Therapeutics, Inc.